Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05962398
Other study ID # CSL222_3003
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date August 30, 2023
Est. completion date March 2035

Study information

Verified date May 2024
Source CSL Behring
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary purpose of this study is to assess the long-term safety in male adults with hemophilia B who were treated with CSL222 in studies CSL222_2001 (NCT03489291) or CSL222_3001 (NCT03569891).


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 56
Est. completion date March 2035
Est. primary completion date March 2035
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Treatment with CSL222 in Study CSL222_2001 or Study CSL222_3001. - Provided written informed consent. - Willing and able to adhere to all protocol requirements. Exclusion Criteria: -

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
AAV5-hFIXco-Padua
Single intravenous infusion of AAV5-hFIXco-Padua in the study CSL222_2001 (NCT03489291) or CSL222_3001 (NCT03569891).

Locations

Country Name City State
United States University of Michigan Medical Center Ann Arbor Michigan
United States Arkansas Children's Hospital - Pharmacology Little Rock Arkansas
United States UC Davis Medical Center Sacramento California
United States University of California, San Diego (UCSD) San Diego California

Sponsors (1)

Lead Sponsor Collaborator
CSL Behring

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs) From Year 5 after administration of CSL222 in parent study up to Year 15
Primary Percentage of Participants With SAEs and AESIs From Year 5 after administration of CSL222 in parent study up to Year 15
Primary Number of SAEs and AESIs From Year 5 after administration of CSL222 in parent study up to Year 15
Secondary Number of Bleeding Episodes The total, spontaneous, traumatic, and joint bleeds will be analyzed. From Year 5 after administration of CSL222 in parent study up to Year 15
Secondary Annualized Bleeding Rate (ABR) The total, spontaneous, traumatic, and joint bleeds will be analyzed. ABR is calculated as the total bleeding episodes divided by the total time at risk. From Year 5 after administration of CSL222 in parent study up to Year 15
Secondary Number of Participants With Zero Bleeds From Year 5 after administration of CSL222 in parent study up to Year 15
Secondary Correlation Analysis of ABR as a Function of Mean Factor IX (FIX) Activity Correlation between ABR and mean FIX activity will be explored using a statistical modeling approach (like, generalized estimating equations [GEE] model for ABR with mean FIX activity as the independent variable). From Year 5 after administration of CSL222 in parent study up to Year 15
Secondary Number of Participants With FIX Activity FIX activity will be assessed using the one-stage activated partial thromboplastin time assay and a chromogenic assay. From Year 5 after administration of CSL222 in parent study up to Year 15
Secondary Number of Participants Using FIX Replacement Therapy From Year 5 after administration of CSL222 in parent study up to Year 15
Secondary Number of Participants Remaining Free of Previous Continuous Routine FIX Prophylaxis From Year 5 after administration of CSL222 in parent study up to Year 15
Secondary Number of Participants With New Target Joints Target joint is defined as 3 or more spontaneous bleeding episodes into a single joint within a consecutive 6-month period. From Year 5 after administration of CSL222 in parent study up to Year 15
Secondary Percentage of Resolution of Target Joints Target joint is defined as 3 or more spontaneous bleeding episodes into a single joint within a consecutive 6-month period. From Year 5 after administration of CSL222 in parent study up to Year 15
Secondary EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Utility Value The EQ-5D-5L questionnaire consists of the EQ-5D-5L descriptive system and the EQ-5D visual analogue scale (VAS). The EQ-5D-5L descriptive system of health-related QoL consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) for which responses will be recorded on 5 levels of severity (no problems, slight problems, moderate problems, severe problems, and extreme problems). The responses will be converted into a single overall health state utility value. This utility value will be derived using the EQ-5D-5L Crosswalk Index Value Calculator v2.xls [Hernández Alava et al, 2023], using the United Kingdom value set. From Year 6 after administration of CSL222 in parent study up to Year 15
Secondary EQ-5D-5L VAS Overall Score The EQ-5D-5L questionnaire consists of the EQ-5D-5L descriptive system and the EQ-5D VAS. The EQ-5D VAS, which measures overall health status on a vertical visual analogue scale, ranges from 0 to 100. A higher score indicates better QoL. From Year 6 after administration of CSL222 in parent study up to Year 15
Secondary Hem-A-QoL Overall Score The Hem-A-QoL (Hemophilia Quality of Life Questionnaire for Adults) consists of 46 items comprising 10 domains: physical health, feelings, treatment, work and school, dealing with hemophilia, family planning, future, partnerships and sexuality, sports and leisure, and view of yourself for which responses will be recorded from 5 options (never, seldom, sometimes, often, and always; for some items, there is also a "not applicable" option). The total score is based on the scores for each domain and ranges from 0 to 100, with lower scores reflecting a better QoL. From Year 6 after administration of CSL222 in parent study up to Year 15
See also
  Status Clinical Trial Phase
Completed NCT04072237 - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia Phase 1
Completed NCT02199717 - An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia N/A
Completed NCT01662531 - A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B Phase 3
Completed NCT01335061 - Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B Phase 3
Completed NCT01217255 - Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
Completed NCT00037557 - Study Evaluating rFIX; BeneFIX in Severe Hemophilia B Phase 3
Completed NCT02554773 - An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B Phase 1/Phase 2
Terminated NCT02807753 - The Hemophilia Ultrasound Project
Active, not recruiting NCT03901755 - An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B
Not yet recruiting NCT05980377 - Patterns of Hemophilia Care in Assiut Children Patients
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Terminated NCT03248141 - Understanding Hemophilia A and B Drug Dosage Administration Patterns
Terminated NCT01460147 - Osteoporosis and MRI Study in Hemophilia N/A
Completed NCT03818529 - ATHN 8: Previously Untreated Patients (PUPs) Matter Study
Completed NCT02571569 - A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors Phase 1
Terminated NCT01620801 - Hemophilia B Gene Therapy With AAV8 Vector Phase 1
Completed NCT01233440 - Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B Phase 1
Active, not recruiting NCT04135300 - Gene Therapy for Chinese Hemophilia B N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Terminated NCT00947193 - Study of Ataluren (PTC124) in Hemophilia A and B Phase 2